Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Clinical Evidence

 

 

Ultimaster Clinical Program https://www.terumo-europe.com/en-emea/the-comprehensive-clinical-programmeUltimaster Clinical Program Global06/09/2018 22:00:00
CENTURY II Trialhttps://www.terumo-europe.com/en-emea/clinicaldata/century-iiCENTURY II Trial05/09/2018 22:00:00<ul><li>Multicentre, intercontinental study: 58 sites in 13 countries across Europe, Japan, and South Korea </li><li>Primary endpoint: freedom from TLF at 9 months</li><li>Secondary endpoint: rate of TVF; patient-oriented composite endpoint; rate of TLR, TVR, ST, cardiac death, MI; composite of cardiac death and MI; rate of bleeding and vascular complications </li><li>Clinical follow-up up to 5 years </li><li>Stage: Published and completed<br></li></ul>
DISCOVERY 1TO3 Trialhttps://www.terumo-europe.com/en-emea/clinicaldata/discovery-1to3-trialDISCOVERY 1TO3 Trial04/09/2018 22:00:0060 MVD patients with OFDI, single arm, primary endpoint TLF @ 12M. Published
Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patientshttps://www.terumo-europe.com/en-emea/clinicaldata/chemoembolization-of-hepatocellular-carcinoma-with-drug-eluting-polyethylene-glycol-embolic-agents-single-center-retrospectiveChemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients03/05/2018 22:00:00​Filipe Veloso Gomes, MBChB, BSc, João A. Oliveira, MD, Mariana Tomé Correia, MD, Nuno Vasco Costa, MD, João Abrantes, MD, Daniel Torres, MD, Pedro Pereira, MD, Ana Isabel Ferreira, MD, José Hugo Luz, MD, Erik Spaepen, MSc, Tiago Bilhim, MD, PhD, and Élia Coimbra, MD
Safety and efficacy of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinomahttps://www.terumo-europe.com/en-emea/clinical-program/Pages/Safety-and-efficacy-of-balloon‐occluded-transcatheter-arterial-chemoembolization-using-miriplatin-for-hepatocellular-carcin.aspxSafety and efficacy of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma19/04/2018 22:00:00<p>​Hirotaka Arai et al Gunma University Graduate School of Medicine, Maebashi, Japan</p>